Application of LncRNA to preparation of lung adenocarcinoma diagnosing reagent
A technology of lung adenocarcinoma, CLDN10-AS1, applied in detection reagents, LncRNA in the field of preparing reagents for diagnosing lung adenocarcinoma, which can solve the problems of complicated and long-term detection of lung adenocarcinoma genes
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0022] 1. LncRNA expression data analysis in lung adenocarcinoma and normal lung tissues
[0023] First, the LncRNA sequencing data of lung adenocarcinoma and lung normal tissues were downloaded from the TCGA database, and a total of 488 lung adenocarcinoma tissues and 58 lung normal tissues were included. The expression level of lncRNA is represented by FPKM value.
[0024] LncRNAs that can be applied to the diagnosis of lung adenocarcinoma lung normal tissues were initially screened based on the following criteria.
[0025] (1) The multiple difference between lung adenocarcinoma and normal tissue is greater than 10.
[0026] (2) P<0.01.
[0027] (3) LncRNAs expressed in lung adenocarcinoma accounted for more than 80%.
[0028] We finally selected 6 LncRNAs and searched for different transcripts of LncRNAs through the Ensembl database. They all had more than one transcript. In order to improve the reliability of the results, DNAstar software was used to analyze their conse...
Embodiment 2
[0068] The use of embodiment 2 kit
[0069] With reference to the method of Example 1, total RNA was extracted from lung adenocarcinoma patient’s cancer tissue specimen and adjacent normal tissue, and after reverse transcription into cDNA, the diagnostic kit of the present invention was used to detect LINC00942, LINC00973, AFAP1-AS1 by RT-PCR , CLDN10-AS1 expression difference in lung adenocarcinoma and adjacent normal tissues.
[0070] The present invention collected surgical resection specimens from patients with primary lung adenocarcinoma in the Department of Thoracic Surgery of Zhongshan Hospital from February 2016 to December 2016. Using the kit of the present invention, the screened LncRNA was verified by QRT-PCR in surgically resected pathological specimens, and it was found that the expressions of LINC00942, LINC00973, AFAP1-AS1, and CLDN10-AS1 were significantly higher in cancer tissues than in paracancerous tissues.
PUM
![No PUM](https://static-eureka-patsnap-com.libproxy1.nus.edu.sg/ssr/23.2.0/_nuxt/noPUMSmall.5c5f49c7.png)
Abstract
Description
Claims
Application Information
![application no application](https://static-eureka-patsnap-com.libproxy1.nus.edu.sg/ssr/23.2.0/_nuxt/application.06fe782c.png)
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com